A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing
Description
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study with 6 month treatment phase and 6 month observation phase.
Details
Age
Child
Eligibility
1. Age range: 6 months to 72 months (5 years)
2. History of wheeze episodes
Locations
Childrens Hospital Colorado
Principal Investigator
Andrew Liu
Study ID
Protocol Number: 23-0534
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers